Neuro-Hitech (OTCBB: NHPI), a biopharmaceutical company focused on the development and commercialization of next-generation compounds against proven targets for neurodegenerative diseases, today announced the formation of the Neuro-Hitech Affiliated Scientific Advisory Board. Bringing together highly respected scientists from related fields, the board will draw upon its members’ unique expertise to offer strategic counsel to the company and help it deliver on its core mission. The board’s first priority is to assist the company in its efforts to further develop Huperzine A, an alkaloid extract of the plant Huperzia serrata that shows promise in early clinical testing as a treatment for Alzheimer’s Disease.
